

UNCLASSIFIED

AD NUMBER
ADB261339
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; May 2000. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702-5012
AUTHORITY
USAMRMC ltr, 8 Jan 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-99-1-9373

TITLE: Total Synthesis of Eleutherobin and Analogs and Study of
Anti-Cancer Mechanism

PRINCIPAL INVESTIGATOR: Qiang Tan, Ph.D.
Samuel Danishefsky, Ph.D.

CONTRACTING ORGANIZATION: Sloan Kettering Institute for Cancer Research
New York, New York 10021

REPORT DATE: May 2000

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, May 00). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

DTIC QUALITY INSPECTED 3

20010108 083

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9373
Organization: Sloan Kettering Institute
Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Kath More 12/19/10

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)

2. REPORT DATE

May 2000

3. REPORT TYPE AND DATES COVERED

Annual Summary (1 Apr 99 - 30 Apr: 00)

4. TITLE AND SUBTITLE

Total Synthesis of Eleutherobin and Analogs and Study of Anti-Cancer Mechanism

5. FUNDING NUMBERS

DAMD17-99-1-9373

6. AUTHOR(S)

Qiang Tan, Ph.D.
Samuel Danishefsky, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Sloan Kettering Institute for Cancer Research
New York, New York 100218. PERFORMING ORGANIZATION
REPORT NUMBER

E-MAIL:

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-501210. SPONSORING / MONITORING
AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, May 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)

A modified eleutherobin synthesis is being studied. Compared to the initial synthesis, the new synthesis is designed to improve the stereoselectivity of key steps and shorten the sequence.

14. SUBJECT TERMS

Breast Cancer

15. NUMBER OF PAGES

12

16. PRICE CODE

17. SECURITY CLASSIFICATION
OF REPORT

Unclassified

18. SECURITY CLASSIFICATION
OF THIS PAGE

Unclassified

19. SECURITY CLASSIFICATION
OF ABSTRACT

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

O.T. Where copyrighted material is quoted, permission has been obtained to use such material.

Q.T. Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Q.T. Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature


April 25, 2000
Date

Table of Contents

Cover.....	
SF 298.....	
Foreword.....	
Table of Contents.....	5
Introduction.....	6
Body.....	7
Key Research Accomplishments.....	9
Reportable Outcomes.....	10
Conclusions.....	11
References.....	12
Appendices.....	N/A


Introduction:

Eleutherobin is a marine natural product discovered in 1994. It serves as one of the most potent anti-cancer agents mimicking Taxol. The proposed research is focused on improving the total synthesis of eleutherobin, and based on that developing eleutherobin analogs for biological studies.




Body:

Scheme 1




The above Scheme 1 outlines the initial synthesis developed in this lab (1). It features an addition of 2-bromo-5-lithiofuran to aldehyde 3 to give the key intermediate 4 (57% yield). The C8 epimer is also isolated as a minor product (ca. 7:5 diastereomeric ratio). Although the epimer can be recycled, the efficiency of the synthesis certainly has a room for improvement.

Scheme 2



Scheme 2 shows the new retrosynthetic plan in which the key intermediate 6 will be obtained through the reduction of ketone 8. Various reducing agents can be screened to optimize the stereoselectivity. Ketone 8 can be synthesized from 9 through a Claisen rearrangement. Prior to that, the C1 side chain can be installed by alkylation utilizing the enone function of (-)-Carvone 10.

Scheme 3



Scheme 3 shows the current work. The yields are approximate since they are still under optimization. (-)-Carvone **10** was selectively hydrogenated at the terminal double bond using Wilkinson's catalyst without affecting the enone function. As a modification to the reported procedure (2), it was discovered that the application of a moderate high pressure (1600 psi) is necessary for an efficient hydrogenation. The dihydrocarvone **11** obtained was then converted to the thermodynamically more favored TMS ether diene **12**. The published procedure (3) uses a catalytical amount of FeCl_3 , but under our hands a 3.0 eq. of FeCl_3 has to be applied to obtain a satisfactory conversion. Lewis acid induced alkylation leads to dimethyl acetal **13** (**4**). The stereoselective reduction of the ketone is achieved with L-Selectride (**4**) to give the alcohol **14**, which was coupled with bromo-furanyl acid **15** to give the ester **16**. Treatment of Tebbe reagent gave **17** which sets up the stage for a Claisen rearrangement to give **8**. Currently, various reducing agents are being tested to reduce C8 ketone to the desired stereoisomer. Work is also being carried out to elongate the C1 side chain by one carbon. Also under study is the idea of installing a two-carbon side chain at C1 in the beginning of the synthesis, which will further shorten the sequence.

Key Research Accomplishments:

Promising results have been obtained on an improved eleutherobin synthesis. Several key steps, including Claisen rearrangement on an advanced intermediate, have been worked out.

Reportable Outcomes:

N/A (early stage of the research).

Conclusions:

An improved eleutherobin synthesis is under development and shows promising results.

Reference:

1. (a) X.-T. Chen, C. E. Gutteridge, S. M. Bhattacharya, B. Zhou, T. P. R. Pettus, T. Hascall, and S. J. Danishefsky *Angew. Chem. Int. Ed.* **1998**, *37*, 185-187. (b) X.-T. Chen, B. Zhou, S. M. Bhattacharya, C. E. Gutteridge, , T. P. R. Pettus, and S. J. Danishefsky *Angew. Chem. Int. Ed.* **1998**, *37*, 789-792.
2. R. E. Ireland and P. Bey *Org. Syn.* VI, 459-460.
3. O. Takazawa, H. Tamura, K. Kogami, and K. Hayashi *Bull. Chem. Soc. Jpn.*, **1982**, 1907-1911.
4. S. Ceccarelli, U. Piarulli, and C. Gennari *Tet. Lett.*, **1999**, 153-156.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

8 Jan 2003

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to the enclosed. Request the limited distribution statement for the enclosed be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

A handwritten signature in black ink, appearing to read "Phyllis M. Rinehart".

PHYLIS M. RINEHART
Deputy Chief of Staff for
Information Management

Encl

ADB265840
ADB279138
ADB264578
ADB281679
ADB281645
ADB261128
ADB261339
ADB273096
ADB281681
ADB259637
ADB256645
ADB262441
ADB281674
ADB281771
ADB281612

ADB266633
ADB251763
ADB281601
ADB258874
ADB281773
ADB281660
ADB259064
ADB266141
ADB281664
ADB258830
ADB266029
ADB281668
ADB259834
ADB266075
ADB281661

ADB282069
ADB265386
ADB282057
ADB258251
ADB264541
ADB241630
ADB281924
ADB281663
ADB281659